By IDSE News Staff
Between 2012 and 2016, the United States saw a decrease in HIV diagnoses due to the use of emtricitabine-tenofovir disoproxil fumarate (FTC/TDF; Truvada, Gilead) for pre-exposure prophylaxis (PrEP), according to data presented at the 2018 International AIDS Conference in Amsterdam.
In the analysis, states with the highest utilization of FTC/TDF for PrEP saw significant declines in the average number of HIV diagnoses, whereas there was an average increase for the states with the